Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug sold under many brand names for angina pectoris (chest pain associated with impaired blood flow to the heart). [1] Trimetazidine is described as the first cytoprotective anti- ischemic agent developed and marketed by Laboratoires Servier (France).

Feb 12, 2022 · Trimetazidine is a drug used to prevent or treat angina attacks—which is a type of chest pain caused by reduced blood flow to the heart—and other heart-related conditions. It works by increasing blood flow to the heart and limits rapid spikes in blood pressure.

Aug 4, 2024 · Trimetazidine (TMZ) is a medication used to treat heart-related conditions like angina. It helps metabolize fatty acids, which helps your body use oxygen.

Mar 19, 2024 · Trimetazidine inhibits fatty acid metabolism and stimulates the metabolism of glucose. It helps the body use oxygen, which relieves chest pain caused by blocked blood vessels. Trimetazidine comes in two strengths:

May 12, 2015 · Trimetazidine is a piperazine derivative indicated as an adjunct therapy in symptomatic treatment of stable angina pectoris.

Trimetazidine is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several—not yet fully understood—mechanisms of action. The best known trimetazidine mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) [1].

Oct 31, 2022 · Trimetazidine is an antianginal agent belonging to the Fatty acid oxidation inhibitors. Trimetazidine is used in the symptomatic treatment of stable angina pectoris.

Dec 4, 2022 · What is trimetazidine? TMZ is an antianginal agent acting at the myocardial cell (heart cell) level and shown to be effective in minimizing angina attacks, nitrate usage and improving functional capacity. It is now available in a once-daily formulation.

Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.

Trimetazidine is an anti-ischemic agent used in the treatment of angina that has been shown to improve cardiac function in HF by shifting cardiac energy metabolism from fatty acids to glucose and increasing ATP production.